| Public funding for transformative drugs: the case of sofosbuvir RE Barenie, J Avorn, FA Tessema, AS Kesselheim Drug discovery today 26 (1), 273-281, 2021 | 22 | 2021 |
| Physicians’ perspectives on FDA approval standards and off-label drug marketing AS Kesselheim, S Woloshin, Z Lu, FA Tessema, KM Ross, LM Schwartz JAMA Internal Medicine 179 (5), 707-709, 2019 | 20 | 2019 |
| high cost of chimeric antigen receptor T-cells: challenges and solutions ERS Cliff, AH Kelkar, DA Russler-Germain, FA Tessema, AJN Raymakers, ... American Society of Clinical Oncology Educational Book 43, e397912, 2023 | 18 | 2023 |
| Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis B Gyawali, FA Tessema, EH Jung, AS Kesselheim JAMA Network Open 2 (8), e199570-e199570, 2019 | 17 | 2019 |
| Generic but expensive: why prices can remain high for off-patent drugs FA Tessema, AS Kesselheim, MA Sinha Hastings LJ 71, 1019, 2019 | 16 | 2019 |
| US spending associated with transition from daily to 3-times-weekly glatiramer acetate BN Rome, FA Tessema, AS Kesselheim JAMA internal medicine 180 (9), 1165-1172, 2020 | 12 | 2020 |
| Internal medicine physicians’ financial relationships with industry: an updated national estimate AS Kesselheim, S Woloshin, Z Lu, FA Tessema, KM Ross, LM Schwartz Journal of General Internal Medicine 34, 195-197, 2019 | 12 | 2019 |
| Patients' knowledge of key messaging in drug safety communications for Zolpidem and Eszopiclone: a national survey AS Kesselheim, MS Sinha, P Rausch, Z Lu, FA Tessema, BM Lappin, ... The Journal of Law, Medicine & Ethics 47 (3), 430-441, 2019 | 9 | 2019 |
| Challenges and opportunities for biomarker validation SP Hey, E D'Andrea, EH Jung, F Tessema, J Luo, B Gyawali, ... The Journal of Law, Medicine & Ethics 47 (3), 357-361, 2019 | 9 | 2019 |
| A new approach to treat childhood leukemia: Novartis' CAR-T Therapy FA Tessema, JJ Darrow The Journal of Law, Medicine & Ethics 45 (4), 692-697, 2017 | 8 | 2017 |
| Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear: Study examines list and net prices of a one-month supply of … A Sarpatwari, FA Tessema, M Zakarian, MN Najafzadeh, AS Kesselheim Health Affairs 40 (5), 772-778, 2021 | 6 | 2021 |
| Changes in erythropoiesis stimulating agent use under a risk evaluation and mitigation strategy (REMS) program A Sarpatwari, M He, FA Tessema, JJ Gagne, AS Kesselheim Drug Safety 44, 327-335, 2021 | 6 | 2021 |
| Physician perceptions of step therapy prescribing requirements MA Fischer, AS Kesselheim, Z Lu, KM Ross, FA Tessema, J Avorn Journal of Managed Care & Specialty Pharmacy 25 (11), 1210-1224, 2019 | 6 | 2019 |
| Randomized study of providing evidence context to mitigate physician misinterpretation arising from off-label drug promotion LM Schwartz, S Woloshin, Z Lu, KM Ross, FA Tessema, D Peter, ... Circulation: Cardiovascular Quality and Outcomes 12 (11), e006073, 2019 | 5 | 2019 |
| Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated: Study examines federal funding for discovery and development of costly … FA Tessema, RE Barenie, J Avorn, AS Kesselheim Health Affairs 42 (5), 642-649, 2023 | 3 | 2023 |
| Sickle cell trait and multisystem trauma: an unaddressed urgent knowledge gap FA Tessema, G Lapping-Carr, MI Affini, IK Selkridge, AY Oppong, ... Trauma Surgery & Acute Care Open 7 (1), e000955, 2022 | 3 | 2022 |
| High-priced sickle cell gene therapies threaten to exacerbate us health disparities and establish new pricing precedents for molecular medicine FA Tessema, A Sarpatwari, LZ Rand, AS Kesselheim Journal of Law, Medicine & Ethics 50 (2), 380-384, 2022 | 3 | 2022 |
| Generic competition for drugs treating rare diseases RF Beall, AE Quinn, AS Kesselheim, FA Tessema, A Sarpatwari The Journal of Law, Medicine & Ethics 48 (4), 789-795, 2020 | 3 | 2020 |
| Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies HS Lalani, FA Tessema, AS Kesselheim, BN Rome Journal of General Internal Medicine, 1-9, 2024 | 2 | 2024 |
| Public Funding for High-Cost Drugs Covered By Medicaid: The Case of Sofosbuvir R Barenie, J Avorn, F Tessema, A Kesselheim 2019 Annual Research Meeting, 2019 | | 2019 |
